Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Net Income towards Common Stockholders (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Net Income towards Common Stockholders for 17 consecutive years, with -$1.6 million as the latest value for Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 48.9% to -$1.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$9.6 million through Jan 2026, down 179.34% year-over-year, with the annual reading at $23.4 million for FY2025, 235.53% up from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 was -$1.6 million at PharmaCyte Biotech, up from -$8.4 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $20.6 million in Q3 2024, with the low at -$8.4 million in Q4 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$1.1 million, with a median of -$1.9 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders crashed 1910.91% in 2024, then surged 445.55% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at -$1.9 million in 2022, then decreased by 20.08% to -$2.3 million in 2023, then crashed by 31.03% to -$3.0 million in 2024, then tumbled by 184.45% to -$8.4 million in 2025, then soared by 81.51% to -$1.6 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$1.6 million, -$8.4 million, and -$8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.